Physician profile
Daniel C Choo
NPI 1154325702
$9,258.45
in general payments reported to CMS, 2019-2025
31 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,007 · 2020: $958 · 2021: $2,714 · 2022: $1,284 · 2023: $1,330 · 2024: $466 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,274 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,274.05 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,284.01 | 2019-2025 | |
| Amarin Pharma, INC. | $1,085.46 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $852.26 | 2019-2025 | Jardiance |
| Amgen INC. | $849.50 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $721.78 | 2020-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $640.31 | 2019-2024 | Camzyos |
| Edwards Lifesciences Corporation | $607.78 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medtronic Vascular, INC. | $578.70 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $517.29 | 2020-2024 | Farxiga |
| Medtronic, INC. | $497.32 | 2021-2023 | Micra, Linq II |
| Janssen Pharmaceuticals, INC | $258.51 | 2019-2024 | Xarelto |
| Abiomed | $180.83 | 2021-2023 | Impella |
| Abbott Laboratories | $173.35 | 2021-2023 | 2nd Gen Centrimag Primary Console |
| Pfizer INC. | $154.41 | 2019-2025 | |
| Biotronik INC. | $143.20 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $131.20 | 2021-2022 | |
| Novo Nordisk INC | $99.89 | 2020-2025 | Rybelsus, Ozempic |
| Lexicon Pharmaceuticals, INC. | $75.89 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $71.66 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $54.00 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $49.46 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $46.49 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $33.51 | 2022 | |
| Gilead Sciences, INC. | $30.44 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $28.15 | 2024 | Arcalyst |
| Akcea Therapeutics, INC. | $24.28 | 2019 | |
| Kestra Medical Technology Services, INC. | $20.43 | 2023 | Assure Wcd |
| Glaxosmithkline, LLC. | $18.79 | 2025 | Shingrix |
| Teleflex LLC | $14.92 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.63 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Choo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.